198 related articles for article (PubMed ID: 37789342)
1. Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
Zhang S; Huang Y; Pi S; Chen H; Ye F; Wu C; Li L; Ye Q; Lin Y; Su Z
J Nanobiotechnology; 2023 Oct; 21(1):360. PubMed ID: 37789342
[TBL] [Abstract][Full Text] [Related]
2. Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression.
Chen X; Huang Y; Chen H; Chen Z; Chen J; Wang H; Li D; Su Z
J Nanobiotechnology; 2022 Jan; 20(1):34. PubMed ID: 35033089
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of anti-PD-1/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework.
Ge YX; Zhang TW; Zhou L; Ding W; Liang HF; Hu ZC; Chen Q; Dong J; Xue FF; Yin XF; Jiang LB
Biomaterials; 2022 Mar; 282():121407. PubMed ID: 35217343
[TBL] [Abstract][Full Text] [Related]
4. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
5. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
6. Perfluorocarbon nanodrug induced oxygen self-enriching sonodynamic therapy improves cancer immunotherapy after insufficient radiofrequency ablation.
Huang T; Wu W; Wu J; Tan Y; Zhang M; Long H; Guo H; Zhang X; Zhou W; Zhang Q; Xie X; Xu M; Zhang C
Front Immunol; 2023; 14():1124152. PubMed ID: 37051250
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
9. Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.
Sun T; Sun B; Cao Y; Liu J; Chen J; Liang B; Zheng C; Kan X
Biomed Pharmacother; 2023 Oct; 166():115351. PubMed ID: 37625323
[TBL] [Abstract][Full Text] [Related]
10. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy.
Zhao Z; Wu J; Liu X; Liang M; Zhou X; Ouyang S; Yao J; Wang J; Luo B
Cancer Lett; 2018 May; 421():73-81. PubMed ID: 29458142
[TBL] [Abstract][Full Text] [Related]
11. Semiconducting Polymer Nanoparticles with Surface-Mimicking Protein Secondary Structure as Lysosome-Targeting Chimaeras for Self-Synergistic Cancer Immunotherapy.
Qi J; Jia S; Kang X; Wu X; Hong Y; Shan K; Kong X; Wang Z; Ding D
Adv Mater; 2022 Aug; 34(31):e2203309. PubMed ID: 35704513
[TBL] [Abstract][Full Text] [Related]
12. ZIF-8 Nanoparticles Evoke Pyroptosis for High-Efficiency Cancer Immunotherapy.
Ding B; Chen H; Tan J; Meng Q; Zheng P; Ma P; Lin J
Angew Chem Int Ed Engl; 2023 Mar; 62(10):e202215307. PubMed ID: 36629270
[TBL] [Abstract][Full Text] [Related]
13. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
[TBL] [Abstract][Full Text] [Related]
14. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
Lai X; Yao F; An Y; Li X; Yang XD
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985529
[TBL] [Abstract][Full Text] [Related]
15. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
[TBL] [Abstract][Full Text] [Related]
16. A PD-L1-targeting Regulator for Metabolic Reprogramming to Enhance Glutamine Inhibition-Mediated Synergistic Antitumor Metabolic and Immune Therapy.
Jin XK; Zhang SM; Liang JL; Zhang SK; Qin YT; Huang QX; Liu CJ; Zhang XZ
Adv Mater; 2024 Feb; 36(6):e2309094. PubMed ID: 38014890
[TBL] [Abstract][Full Text] [Related]
17. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
18. Combining dual-targeted liquid metal nanoparticles with autophagy activation and mild photothermal therapy to treat metastatic breast cancer and inhibit bone destruction.
Shen Y; Zou Y; Bie B; Dong C; Lv Y
Acta Biomater; 2023 Feb; 157():578-592. PubMed ID: 36442822
[TBL] [Abstract][Full Text] [Related]
19. Size-Tunable Nanoregulator-Based Radiofrequency Ablation Suppresses MDSCs and Their Compensatory Immune Evasion in Hepatocellular Carcinoma.
Tang Y; Shu Z; Zhu M; Li S; Ling Y; Fu Y; Hu Z; Wang J; Yang Z; Liao J; Xu L; Yu M; Peng Z
Adv Healthc Mater; 2023 Dec; 12(30):e2302013. PubMed ID: 37665720
[TBL] [Abstract][Full Text] [Related]
20. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
